P-gp、GST-π、TOPO-Ⅱ、LRP在大肠癌中的表达及临床意义

Expression and clinical significance of P-gp,GST-π,TOPO-Ⅱ and LRP in colorectal carcinoma

目的探讨P-gp、GST-π、TOPO-Ⅱ、LRP在大肠癌中的表达情况及临床意义。方法应用免疫组化方法(PV-6000法)检测P-gp、GST-π、TOPO-Ⅱ、LRP在58例大肠癌根治术标本中的表达。结果58例大肠癌中P-gp、GST-π、TOPO-Ⅱ和LRP的阳性率分别为75·9%,70·7%,56·9%和65·5%。P-gp表达与淋巴结转移有关,与分化类型、Dukes分期、浸润深度无关。GST-π、TOPO-Ⅱ、LRP及四者联合表达与各项病理特征无关。结论P-gp、GST-π、TOPO-Ⅱ、LRP等联合作用是大肠癌多药耐药性的主要作用机制,检测患者P-gp、GST-π、TOPO-Ⅱ、LRP的表达对大肠癌的化疗药物和方案选择具有参考意义。

Objective To evaluate the expression and clinical significance of P-gp, GST-π, TOPO-Ⅱ and LRP in colorectal carcinoma. Methods The expressions of P-gp, GST-π, TOPO-Ⅱ and LRP in 58 cases with colorectal carcinoma were examined using immunohistochemistry PV-6000 method. Results Of 58 cases of colorectal carcinoma, the positive expression rates of P-gp,GST-π, TOPO-Ⅱ and LRP were 75. 9% , 70. 7%, 56.9% and 65. 5%, respectively. The expression of P-gp was related to lymph nod metastasis, but not related to histological grade , Dukes stage and local invasion. No relation could be established between the expression of GST-π, TOPO-Ⅱ , LRP and clinicopathological features. Conclusion The combined effect of P-gp, GST-π, TOPO-Ⅱ and LRP may be an important mechanism of multidrug resistance of the patients with coloreetal carcinoma. Detecting the expression of P-gp, GST-π, TOPO-Ⅱ and LRP has the referential significance with regard to the choice of drugs and plan in colorectal carcinoma chemotherapy.